BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25152312)

  • 41. A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies.
    Grønbæk K; Müller-Tidow C; Perini G; Lehmann S; Bach Treppendahl M; Mills K; Plass C; Schlegelberger B;
    Haematologica; 2012 Sep; 97(9):1380-8. PubMed ID: 22491733
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia.
    Najfeld V; Tripodi J; Scalise A; Silverman LR; Silver RT; Fruchtman S; Hoffman R
    Br J Haematol; 2010 Nov; 151(3):288-91. PubMed ID: 20738298
    [No Abstract]   [Full Text] [Related]  

  • 43. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of ras gene mutations in myeloproliferative disorders.
    Liu ET
    Clin Lab Med; 1990 Dec; 10(4):797-807. PubMed ID: 2272174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.
    Hogg G; Severson EA; Cai L; Hoffmann HM; Holden KA; Fitzgerald K; Kenyon A; Zeng Q; Mooney M; Gardner S; Chen W; Nagan N; Boles D; Parker S; Richman TJ; Letovsky S; Dong H; Anderson SM; Ramkissoon S; Reddy P; Eisenberg M; Chenn A; Jensen TJ
    Cancer Genet; 2023 Nov; 278-279():38-49. PubMed ID: 37586297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation.
    Juopperi TA; Bienzle D; Bernreuter DC; Vernau W; Thrall MA; McManus PM
    Vet Pathol; 2011 Jan; 48(1):182-97. PubMed ID: 21139142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
    Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
    Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
    Fernandez-Mercado M; Pellagatti A; Di Genua C; Larrayoz MJ; Winkelmann N; Aranaz P; Burns A; Schuh A; Calasanz MJ; Cross NC; Boultwood J
    Br J Haematol; 2013 Oct; 163(2):235-9. PubMed ID: 23889083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
    Vantyghem S; Peterlin P; Thépot S; Ménard A; Dubruille V; Debord C; Guillaume T; Garnier A; Le Bourgeois A; Wuilleme S; Godon C; Theisen O; Eveillard M; Delaunay J; Maisonneuve H; Morineau N; Villemagne B; Vigouroux S; Subiger F; Lestang E; Loirat M; Parcelier A; Godmer P; Mercier M; Trebouet A; Luque Paz D; Le Calloch R; Le Clech L; Bossard C; Moreau A; Ugo V; Hunault M; Moreau P; Le Gouill S; Chevallier P; Béné MC; Le Bris Y
    Haematologica; 2021 Mar; 106(3):701-707. PubMed ID: 32241844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition.
    Gurbuxani S; Hochman MJ; DeZern AE; Shimamura A
    Am Soc Clin Oncol Educ Book; 2023 Jun; 43():e390026. PubMed ID: 37307513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recurrent genetic defects on chromosome 7q in myeloid neoplasms.
    Hosono N; Makishima H; Jerez A; Yoshida K; Przychodzen B; McMahon S; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Gómez-Seguí I; Verma AK; McDevitt MA; Sekeres MA; Ogawa S; Maciejewski JP
    Leukemia; 2014 Jun; 28(6):1348-51. PubMed ID: 24429498
    [No Abstract]   [Full Text] [Related]  

  • 53. Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes.
    Bartram CR
    Blood Cells; 1988; 14(2-3):533-8. PubMed ID: 3067784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.
    Sakr R; Renneville A; Saada V; Cotteret S; Martin JE; Droin N; Selimoglu-Buet D; Besse B; Hollebecque A; Marzac C; Pasquier F; Micol JB; De Botton S; Mir O; Solary E; Willekens C
    Leuk Lymphoma; 2018 Jul; 59(7):1742-1745. PubMed ID: 29115897
    [No Abstract]   [Full Text] [Related]  

  • 55. Cohesin mutations in myeloid malignancies made simple.
    Viny AD; Levine RL
    Curr Opin Hematol; 2018 Mar; 25(2):61-66. PubMed ID: 29278534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Classification of myeloid leukemias].
    Kuriyama K
    Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
    So CC; Ma ES; Wan TS; Yip SF; Chan LC
    Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
    [No Abstract]   [Full Text] [Related]  

  • 58. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
    Harada H; Harada Y
    Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Molecular mechanisms of myeloid malignancies].
    Matsui H
    Rinsho Ketsueki; 2021; 62(8):883-891. PubMed ID: 34497227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.